Author

P. Herzig

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1

Frequent Co-Authors

A. Zippelius· 2 shared D. Lardinois· 2 shared A. Boersch· 1 shared A. Zingg· 1 shared E. Carlini· 1 shared F. Bieberich· 1 shared H. Jin· 1 shared H. Laeubli· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Zippelius

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Multimodal single-cell profiling of T cell specificity and reactivity in lung cancer

F. Bieberich, R. Vazquez-Lombardi, H. Jin, K.-L. Hong, P. Herzig, M. Trefny, M. Trueb, H. Laubli, D. Lardinois, K. Mertz, M. Matter, A. Zippelius, S. T. Reddy

This study uses multimodal single-cell profiling to analyze T cell specificity and reactivity in lung cancer patients, identifying tumor- and virus-reactive T cells and their functional states.

bioRxiv · Oct 4, 2023 · PreprintImmunology

Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2

R. Wieboldt, E. Carlini, L. Chia-wei, A. Boersch, A. Zingg, D. Lardinois, P. Herzig, L. Don, A. Zippelius, H. Laeubli, N. Rodrigues Mantuano

This study shows that sialylated glycans on myeloid suppressor cells interact with Siglec receptors to suppress anti-cancer immunity through CCL2-mediated mechanisms.

bioRxiv · Jun 29, 2023 · PreprintImmunology